Aim: Gastric disease is the most powerful type of malignant growth. The immunohistochemical articulation of the proteins of the p53 has been proposed as a potential device to evaluate the natural conduct of gastric malignant growth. The research aim was of p53 for endurance is questionable; henceforth this examination has been detailed to know the endurance of patients with p53 joints in gastric diseases. Methods: Our current research was led at Jinnah Hospital, Lahore from May 2018 to April 2019, including 64 patients back-to-back gastric malignant growth. Examples of biopsies were treated in immunohistochemistry and the articulation of p53 quality was decomposed by immunoreactive score (IRS). These findings were then contrasted and clinically obsessive parameters such as age, sexual orientation, tumor area, tumor size, Laurens characterization and TNM organization as indicated by the joint U.S. Board of Directors for the rules of disease, using CT belly exit, and histopathological evaluation and types as indicated by WHO arrangement. RESULTS: Mp53 joint was observed in 95% of patients with gastric malignancy, with 39 (64.9%) having a high joint and 22 (38.3%) having a low p53 joint. The joint level p53 was found to be essentially related to age, tumor site, tumor size, histological evaluation, T organization, M arrangement and clinical stage. A multivariate study shows that a high p53 joint is a free indicator of endurance. At the Kaplan-Meier endurance examination, patients with a high p53 joint had a significantly shorter overall endurance than patients with a low p53 joint. Conclusion: The expression of p53 is associated with endurance and is a basic, binding and reproducible methodology for deciding on prediction and endurance in the different assessments and phases of gastric disease. Key words: Gastric cancer; Gene expression; Immunohistochemistry.